Clinical trials: Gastroparesis With Diabetes Mellitus
Gastroparesis, Diabetes Mellitus
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03426345
- Testing
- Relamorelin
- Where
- 240 sites in United States, Argentina and 13 more
- Volunteers
- 311 people
- Sponsor
- Allergan
Diabetic Gastroparesis
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
A pilot study to assess the safety, feasibility, and potential (uncontrolled) efficacy of continuous glucose monitoring (CGMS) in conjunction with an insulin pump to improve glycemic control for treatment of type 1 and type 2…
- Trial name
- GLUMIT-DG (NCT01030341)
- Testing
- CGMS and insulin pump
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diabetes Mellitus, Diabetes Mellitus Complications
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT02357420
- Testing
- Relamorelin
- Where
- 98 sites in United States, Belgium and 5 more
- Volunteers
- 393 people
- Sponsor
- Allergan
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03285308
- Testing
- Relamorelin
- Where
- 216 sites in United States, Australia and 12 more
- Volunteers
- 336 people
- Sponsor
- Allergan
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying).
- Trial name
- NCT00432835
- Testing
- Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Mississippi Medical Center
Gastroparesis, Diabetic Gastroparesis
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
To evaluate the safety and the effectiveness of two doses of metoclopramide nasal spray solution, 10 mg and 14 mg, compared to placebo in reducing the symptoms of diabetic gastroparesis.
- Conditions
- Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus
- Trial name
- NCT00845858
- Testing
- metoclopramide
- Where
- 65 sites in United States
- Volunteers
- 287 people
- Sponsor
- Evoke Pharma
Diabetes, Gastroparesis With Diabetes Mellitus
PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans.
- Trial name
- NCT04762719
- Testing
- PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Diabetic Gastroparesis
Thoracic Neuromodulation for Diabetic Gastroparesis
The global incidence of diabetes is rising. Gastroparesis is a significant complication of diabetes that results in debilitating symptoms and affects quality of life.
- Trial name
- TNM-DGp (NCT05273788)
- Testing
- 2400 ThorS-MagNT Stimulations at 1Hz, 2400 ThorS-MagNT Stimulations at 10Hz
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Gastroparesis With Diabetes Mellitus
Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis
The device being studied, the Transcutaneous Electrical Accustimulator (TEA), will deliver weak electrical current at two specific points, one at the leg and the other at the arm at settings known to improve symptoms involving…
- Trial name
- NCT05362578
- Testing
- transcutaneous electrical accustimulation at treatment point.
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Michigan
Diabetic Gastroparesis
A Scintigraphy Study in Adults With Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
- Trial name
- NCT04208698
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis
Diabetic Gastroparesis Study 05
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 [NCT03420781] or RLM-MD-04 [NCT03383146] study and to provide treatment for these…
- Trial name
- NCT03786380
- Testing
- Relamorelin 10 μg
- Where
- 486 sites in United States, Argentina and 28 more
- Volunteers
- 202 people
- Sponsor
- Allergan
Gastroparesis
Different Doses of Naronapride vs. Placebo in Gastroparesis
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to…
- Trial name
- MOVE-IT (NCT05621811)
- Testing
- Naronapride
- Where
- 24 sites in United States, Belgium
- Volunteers
- 328 people
- Sponsor
- Dr. Falk Pharma GmbH
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.
- Trial name
- NCT02025725
- Testing
- Metoclopramide Nasal Spray
- Where
- 50 sites in United States
- Volunteers
- 205 people
- Sponsor
- Evoke Pharma
Gastroparesis
Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)
- Trial name
- NCT01135186
- Testing
- sapropterin dihydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
A Study of CNSA-001 in Women With Diabetic Gastroparesis
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or…
- Trial name
- NCT03712124
- Testing
- CNSA-001
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- PTC Therapeutics
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
- Trial name
- NCT03383146
- Testing
- Relamorelin
- Where
- 349 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Allergan